Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Therapy With Biologic Agents After Diagnosis of Solid Malignancies: Results From the Corrona Registry.

Pappas DA, Rebello S, Liu M, Schenfeld J, Li Y, Collier DH, Accortt NA.

J Rheumatol. 2019 Apr 1. pii: jrheum.171457. doi: 10.3899/jrheum.171457. [Epub ahead of print]

2.

A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population.

Paller AS, Schenfeld J, Accortt NA, Kricorian G.

Pediatr Dermatol. 2019 May;36(3):290-297. doi: 10.1111/pde.13772. Epub 2019 Feb 21.

PMID:
30791141
3.

Utility of administrative and clinical data to predict major change in medical treatment in US Veterans enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry.

Stever JR, Cannon GW, Teng CC, Accortt NA, Collier DH, Sauer BC.

Clin Exp Rheumatol. 2018 Nov 12. [Epub ahead of print]

PMID:
30418115
4.

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.

Sparks JA, Lesperance T, Accortt NA, Solomon DH.

Arthritis Care Res (Hoboken). 2019 Apr;71(4):512-520. doi: 10.1002/acr.23609.

PMID:
29799667
5.

Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis.

Accortt NA, Lesperance T, Liu M, Rebello S, Trivedi M, Li Y, Curtis JR.

Arthritis Care Res (Hoboken). 2018 May;70(5):679-684. doi: 10.1002/acr.23426. Epub 2018 Mar 11.

6.

Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations.

Accortt NA, Chung JB, Bonafede M, Limone BL, Mannino DM.

Int J Chron Obstruct Pulmon Dis. 2017 Jul 19;12:2085-2094. doi: 10.2147/COPD.S127815. eCollection 2017.

7.

Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis.

Accortt NA, Schenfeld J, Chang E, Papoyan E, Broder MS.

Adv Ther. 2017 Sep;34(9):2093-2103. doi: 10.1007/s12325-017-0596-6. Epub 2017 Aug 2.

8.

Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use.

Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C.

Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1109-1118. doi: 10.1002/pds.4261. Epub 2017 Jul 31.

PMID:
28758274
9.

Models solely using claims-based administrative data are poor predictors of rheumatoid arthritis disease activity.

Sauer BC, Teng CC, Accortt NA, Burningham Z, Collier D, Trivedi M, Cannon GW.

Arthritis Res Ther. 2017 May 8;19(1):86. doi: 10.1186/s13075-017-1294-0.

10.

Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis.

Schenfeld J, Iles J, Trivedi M, Accortt NA.

Rheumatol Int. 2017 Jul;37(7):1075-1082. doi: 10.1007/s00296-017-3679-4. Epub 2017 Mar 2.

11.

Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.

Mease PJ, Lesperance T, Liu M, Collier DH, Mason M, Deveikis S, Accortt NA.

J Rheumatol. 2017 Feb;44(2):184-192. doi: 10.3899/jrheum.160343. Epub 2017 Jan 15.

PMID:
28089969
12.

Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis.

Radner H, Lesperance T, Accortt NA, Solomon DH.

Arthritis Care Res (Hoboken). 2017 Oct;69(10):1510-1518. doi: 10.1002/acr.23171. Epub 2017 Sep 7.

13.

Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.

Accortt NA, Bonafede MM, Collier DH, Iles J, Curtis JR.

Arthritis Rheumatol. 2016 Jan;68(1):67-76. doi: 10.1002/art.39416.

14.

Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States.

Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D.

Br J Dermatol. 2015 Nov;173(5):1183-90. doi: 10.1111/bjd.14068. Epub 2015 Oct 11.

PMID:
26265015
15.

OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.

Kimball AB, Rothman KJ, Kricorian G, Pariser D, Yamauchi PS, Menter A, Teller CF, Aras G, Accortt NA, Hooper M, Rice KC, Gelfand JM.

J Am Acad Dermatol. 2015 Jan;72(1):115-22. doi: 10.1016/j.jaad.2014.08.050. Epub 2014 Sep 26.

16.

Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09.

Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D.

Br J Dermatol. 2014 Feb;170(2):366-73. doi: 10.1111/bjd.12744.

PMID:
24251402
17.

The effect of delay time between primary melanoma biopsy and sentinel lymph node dissection on sentinel node status, recurrence, and survival.

Parrett BM, Accortt NA, Li R, Dosanjh AS, Thummala S, Kullar R, Cleaver JE, Kashani-Sabet M, Leong SP.

Melanoma Res. 2012 Oct;22(5):386-91. doi: 10.1097/CMR.0b013e32835861f6.

PMID:
22955010
18.

Risk of arterial thrombotic events in inflammatory bowel disease.

Ha C, Magowan S, Accortt NA, Chen J, Stone CD.

Am J Gastroenterol. 2009 Jun;104(6):1445-51. doi: 10.1038/ajg.2009.81. Epub 2009 Apr 21.

PMID:
19491858
19.

Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis.

Kane SV, Accortt NA, Magowan S, Brixner D.

Aliment Pharmacol Ther. 2009 Apr 15;29(8):855-62. doi: 10.1111/j.1365-2036.2009.03941.x. Epub 2009 Jan 17.

20.

Follow-up schedules after treatment for malignant melanoma.

Francken AB, Accortt NA, Shaw HM, Colman MH, Wiener M, Soong SJ, Hoekstra HJ, Thompson JF.

Br J Surg. 2008 Nov;95(11):1401-7. doi: 10.1002/bjs.6347.

PMID:
18844268
21.

Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.

Francken AB, Accortt NA, Shaw HM, Wiener M, Soong SJ, Hoekstra HJ, Thompson JF.

Ann Surg Oncol. 2008 May;15(5):1476-84. doi: 10.1245/s10434-007-9717-9. Epub 2008 Jan 15.

PMID:
18196345
22.

Impact of multiple lymphatic channel drainage to a single nodal basin on outcomes in melanoma.

Wall JK, Florero M, Accortt NA, Allen R, Kashani-Sabet M, Morita E, Leong SP.

Arch Surg. 2007 Aug;142(8):753-7; discussion 756-8.

PMID:
17709729
23.

Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines.

Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF.

Ann Surg Oncol. 2007 Jun;14(6):1924-33. Epub 2007 Mar 15.

PMID:
17357855
24.

Enteroviral meningitis: natural history and outcome of pleconaril therapy.

Desmond RA, Accortt NA, Talley L, Villano SA, Soong SJ, Whitley RJ.

Antimicrob Agents Chemother. 2006 Jul;50(7):2409-14.

25.

Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation.

McGuire BM, Julian BA, Bynon JS Jr, Cook WJ, King SJ, Curtis JJ, Accortt NA, Eckhoff DE.

Ann Intern Med. 2006 May 16;144(10):735-41.

PMID:
16702589
26.

Promotion of acellular dermal matrix resolution in vitro by matrix metalloproteinase-2.

Lindman JP, Talbert M, Zhang W, Powell B, Accortt NA, Rosenthal EL.

Arch Facial Plast Surg. 2006 May-Jun;8(3):208-12.

PMID:
16702534
27.

Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients.

Leong SP, Accortt NA, Essner R, Ross M, Gershenwald JE, Pockaj B, Hoekstra HJ, Garberoglio C, White RL Jr, Chu D, Biel M, Charney K, Wanebo H, Avisar E, Vetto J, Soong SJ; Sentinel Lymph Node Working Group.

Arch Otolaryngol Head Neck Surg. 2006 Apr;132(4):370-3.

PMID:
16618904
28.

Distribution of health care expenditures for HIV-infected patients.

Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA, Stone BK, Carter J, Call S, Pisu M, Allison J, Saag MS.

Clin Infect Dis. 2006 Apr 1;42(7):1003-10. Epub 2006 Feb 22.

PMID:
16511767
29.

Need to educate primary caregivers about the risk factor profile of smokeless tobacco users.

Accortt NA, Waterbor JW, Beall C, Howard G, Brooks CM.

J Cancer Educ. 2005 Winter;20(4):222-8.

PMID:
16497134
30.

Cancer incidence among a cohort of smokeless tobacco users (United States).

Accortt NA, Waterbor JW, Beall C, Howard G.

Cancer Causes Control. 2005 Nov;16(9):1107-15.

PMID:
16184477
31.

Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002.

Bedimo R, Chen RY, Accortt NA, Raper JL, Linn C, Allison JJ, Dubay J, Saag MS, Hoesley CJ.

Clin Infect Dis. 2004 Nov 1;39(9):1380-4. Epub 2004 Oct 11.

PMID:
15494916
32.

The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.

Francken AB, Shaw HM, Thompson JF, Soong SJ, Accortt NA, Azzola MF, Scolyer RA, Milton GW, McCarthy WH, Colman MH, McGovern VJ.

Ann Surg Oncol. 2004 Apr;11(4):426-33. Epub 2004 Mar 15.

PMID:
15070604
33.

Disparities between public health educational materials and the scientific evidence that smokeless tobacco use causes cancer.

Waterbor JW, Adams RM, Robinson JM, Crabtree FG, Accortt NA, Gilliland J.

J Cancer Educ. 2004 Spring;19(1):17-28. Review.

PMID:
15059752
34.

Chronic disease mortality in a cohort of smokeless tobacco users.

Accortt NA, Waterbor JW, Beall C, Howard G.

Am J Epidemiol. 2002 Oct 15;156(8):730-7.

PMID:
12370161

Supplemental Content

Loading ...
Support Center